biostudies-literatureLin YLHealth Science Promotion Project of Beijing; Beijing Natural Science FoundationSpecial Fund for the Capital Characteristic Clinical Medicine Development ProjectBeijing Municipal Administration of Hospitals’ Ascent PlanBeijing Municipal Grant for Medical Talents Group on Peritoneal Surface Oncology1104-1114https://www.ebi.ac.uk/biostudies/studies/S-EPMC6997068biostudies-literatureUnknown9(3)<h4>Background</h4>Pseudomyxoma peritonei (PMP) is an indolent malignancy and insensitive to systemic chemotherapy. The authors established patient-derived xenograft (PDX) model of PMP, and evaluated the efficacy and toxicity of intraperitoneal (i.p.) administration of 5-fluorouracil (5-FU) in this model.<h4>Methods</h4>Human PMP sample was collected to establish subcutaneous (s.c.) and i.p.<h4>Model</h4>In vivo study of i.p. injection of 5-FU was performed in i.p. model, with experimental peritoneal cancer index (ePCI) score and pathological examinations for evaluating the efficacy and toxicity.<h4>Results</h4>Both s.c. and i.p. models were constructed. The average passage interval of s.c. model was 44.2 ± 5.2 days, and the i.p. model was characterized by disseminated solid tumor nodules Cancer medicineEstablishment of patient-derived xenograft model of peritoneal mucinous carcinomatosis with signet ring cells and in vivo study on the efficacy and toxicity of intraperitoneal injection of 5-fluorouracil.PMC69970682017400003235J007DFL201807017172108Z161100000516077Xu HBMa RChen QLi YZhang JJiang XLin YLYang ZRPeng ZYan FCfalseEstablishment of patient-derived xenograft model of peritoneal mucinous carcinomatosis with signet ring cells and in vivo study on the efficacy and toxicity of intraperitoneal injection of 5-fluorouracil.<h4>Background</h4>Pseudomyxoma peritonei (PMP) is an indolent malignancy and insensitive to systemic chemotherapy. The authors established patient-derived xenograft (PDX) model of PMP, and evaluated the efficacy and toxicity of intraperitoneal (i.p.) administration of 5-fluorouracil (5-FU) in this model.<h4>Methods</h4>Human PMP sample was collected to establish subcutaneous (s.c.) and i.p.<h4>Model</h4>In vivo study of i.p. injection of 5-FU was performed in i.p. model, with experimental peritoneal cancer index (ePCI) score and pathological examinations for evaluating the efficacy and toxicity.<h4>Results</h4>Both s.c. and i.p. models were constructed. The average passage interval of s.c. model was 44.2 ± 5.2 days, and the i.p. model was characterized by disseminated solid tumor nodules 2020-01-01T00:00:00Z2020 Feb2025-05-31T23:16:29.826Z2021-02-19T11:40:52ZS-EPMC69970683181432310.1002/cam4.2766